JP2020178581A - Fat active metabolism improving composition - Google Patents
Fat active metabolism improving composition Download PDFInfo
- Publication number
- JP2020178581A JP2020178581A JP2019082489A JP2019082489A JP2020178581A JP 2020178581 A JP2020178581 A JP 2020178581A JP 2019082489 A JP2019082489 A JP 2019082489A JP 2019082489 A JP2019082489 A JP 2019082489A JP 2020178581 A JP2020178581 A JP 2020178581A
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- glutathione
- composition
- fat
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 230000004060 metabolic process Effects 0.000 title abstract description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 53
- 108010024636 Glutathione Proteins 0.000 claims abstract description 26
- 229960003180 glutathione Drugs 0.000 claims abstract description 25
- 229960004203 carnitine Drugs 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract 4
- 230000037356 lipid metabolism Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 5
- 230000006372 lipid accumulation Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 abstract description 12
- 210000001789 adipocyte Anatomy 0.000 abstract description 8
- 210000000577 adipose tissue Anatomy 0.000 abstract description 7
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 22
- 235000003969 glutathione Nutrition 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- -1 carnitine sodium salt Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- GADIJPCDIWZEMB-BTNVMJJCSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O GADIJPCDIWZEMB-BTNVMJJCSA-N 0.000 description 1
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
本発明は、グルタチオン及びカルニチンを有効成分として含むに脂質代謝改善剤及び改善方法に関する。 The present invention relates to a lipid metabolism improving agent and an improving method containing glutathione and carnitine as active ingredients.
近年、世界的に肥満化傾向が顕著になってきており、体脂肪の蓄積という肥満だけでなく、高脂血症、高血圧、糖尿病など生活習慣病の増加が問題となっている。 In recent years, the tendency toward obesity has become remarkable worldwide, and not only obesity such as accumulation of body fat but also increase in lifestyle-related diseases such as hyperlipidemia, hypertension and diabetes has become a problem.
体脂肪の減少には、運動、特に有酸素運動が体脂肪の減少に有効とされているが、移動手段の発達、生活環境の改善などで歩行などの軽度な運動が減少し、有酸素運動により、体脂肪を減少させることが難しくなっている。 Exercise, especially aerobic exercise, is said to be effective in reducing body fat, but mild exercise such as walking decreases due to the development of transportation means and improvement of living environment, and aerobic exercise This makes it difficult to reduce body fat.
Ｌ−カルニチンは、細胞内のミトコンドリア内膜に存在するアミノ酸の一つで、脂肪酸をミトコンドリア内に取り込み脂肪酸をエネルギーとして使用する際に使用され、脂質代謝に関与していることが知られているため、体脂肪減少効果があるとされているが、その効果は充分ではないと記載されている（特許文献１）。そこで、カルニチンと他の成分との組み合わせが検討されている。例えば、特許文献２では、大豆レシチンなどの主成分として含まれるホスファチジルコリンを、脱アシル化することにより得られるグリセロホスホコリンと組み合わせ、特許文献３では、ハス胚芽の抽出物との組み合わせを開示している。 L-carnitine is one of the amino acids present in the inner mitochondrial membrane of cells, and is used when fatty acids are taken into mitochondria and used as energy, and is known to be involved in lipid metabolism. Therefore, it is said that it has a body fat reducing effect, but it is described that the effect is not sufficient (Patent Document 1). Therefore, a combination of carnitine and other components is being studied. For example, Patent Document 2 discloses a combination of phosphatidylcholine contained as a main component of soybean lecithin and the like with glycerophosphocholine obtained by deacylation, and Patent Document 3 discloses a combination with an extract of sacred germ. There is.
そこで、本発明では、体脂肪減少や肥満防止などの効果を有する組成物を得ることを課題として、鋭意検討を行った。その結果、カルニチン及びグルタチオンを配合した組成物は、脂肪細胞への分化を抑制することを見出し本発明を完成させた。 Therefore, in the present invention, an earnest study has been carried out with the object of obtaining a composition having effects such as reduction of body fat and prevention of obesity. As a result, it was found that the composition containing carnitine and glutathione suppresses the differentiation into adipocytes, and completed the present invention.
本発明は、カルニチン及びグルタチオンを含有することを特徴とする脂肪細胞への分化抑制し、脂質蓄積抑制する組成物、または脂質代謝を活性化する組成物である。
（１）カルニチン及びグルタチオンを含有する脂質蓄積抑制用組成物
（２）カルニチン及びグルタチオンを含有する脂質代謝活性用組成物
（３）前記（１）または（２）の組成物を含む食品
（４）前記（１）または（２）の組成物を含む医薬品
The present invention is a composition that suppresses differentiation into adipocytes and suppresses lipid accumulation, or a composition that activates lipid metabolism, which is characterized by containing carnitine and glutathione.
(1) A composition for suppressing lipid accumulation containing carnitine and glutathione (2) A composition for activating lipid metabolism containing carnitine and glutathione (3) A food containing the composition of (1) or (2) above (4) A pharmaceutical product containing the composition of (1) or (2).
本発明は、脂肪細胞への分化を抑制するため、体内脂肪の蓄積を抑制する効果などを有する食品等に利用することができる。グルタチオンは、酵母等に含まれているため、酵母や酵母エキス含有のグルタチオンとカルニチンとを組み合わせると酵母や酵母エキスが持つ栄養成分も同時に摂取でき、代謝改善機能を有する調味料などの食品として使用することもできる。 Since the present invention suppresses differentiation into adipocytes, it can be used for foods and the like having an effect of suppressing the accumulation of fat in the body. Since glutathion is contained in yeast, etc., when glutathion containing yeast or yeast extract is combined with carnitine, the nutritional components of yeast or yeast extract can be taken at the same time, and it is used as a food such as seasoning having a metabolism improving function. You can also do it.
カルニチンは、Ｌ−カルニチン、Ｄ−カルニチン、及びＤＬ−カルニチンなどがある。これらのカルニチンは、塩または誘導体の形態のものを用いることもできる。また、カルニチンの塩も利用することができる。カルニチンの塩は、例えばカルニチンナトリウム塩、カルニチンカリウム塩、カルニチン酒石酸塩およびカルニチンフマル酸塩等がある（以下カルニチン類）。本発明はこれらのカルニチン類を単独または複数組み合わせて利用することができる。特にＬ−カルニチンは、体内にリジン及びメチオニンから合成される。さらに、牛肉、豚肉等の畜肉に含まれており、安全性の高い物質であるため、特に好ましく利用することができる。 Carnitine includes L-carnitine, D-carnitine, DL-carnitine and the like. These carnitines can also be used in the form of salts or derivatives. Carnitine salts can also be used. Examples of the carnitine salt include carnitine sodium salt, carnitine potassium salt, carnitine tartrate and carnitine fumarate (hereinafter referred to as carnitines). In the present invention, these carnitines can be used alone or in combination of two or more. In particular, L-carnitine is synthesized in the body from lysine and methionine. Further, since it is contained in livestock meat such as beef and pork and is a highly safe substance, it can be particularly preferably used.
本発明でいうグルタチオンは、還元型グルタチオン、酸化型グルタチオンあるいはこれらの混合物をいう。還元型グルタチオンとはγ − Ｌ − Ｇ ｌ ｕ − Ｌ − Ｃ ｙ ｓ − Ｇ ｌ ｙ の構造を有するトリペプチドを表し、酸化型グルタチオンとは還元型グルタチオン２ 分子がＳ Ｓ 結合により結合したものである。グルタチオンの形態は、グルタチオンを有効成分として含有するものであれば何でもよい。 Glutathione as used in the present invention refers to reduced glutathione, oxidized glutathione, or a mixture thereof. Reduced glutathione represents a tripeptide having a structure of γ-L-G l u-L-Cy s-G l y, and oxidized glutathione is a substance in which two reduced glutathione molecules are bound by an SS bond. is there. The form of glutathione may be any form as long as it contains glutathione as an active ingredient.
グルタチオンは、例えば酵母や酵母エキス中に含むものを利用しても良い。グルタチオンを多く酵母としては、「ハイチオンコーボＭＧ」（興人ライフサイエンス社製）、グルタチオンを含有する酵母エキスとしては「ハイチオンエキスＹＨ」（興人ライフサイエンス社製）などがある。 As glutathione, for example, those contained in yeast or yeast extract may be used. Examples of yeasts containing a large amount of glutathione include "Haition Cobo MG" (manufactured by Kojin Life Science Co., Ltd.), and yeast extracts containing glutathione include "Haitiion Extract YH" (manufactured by Kojin Life Science Co., Ltd.).
本願では、前段のグルタチオン及びカルニチン類を有効成分として含むものを投与する。投与の方法は、特に限定されず、経口投与、静脈内、腹膜内もしくは皮下投与等の非経口投与をあげることができる。具体的には、錠剤、散剤、顆粒剤、丸剤、懸濁剤、乳剤、浸剤・煎剤、カプセル剤、シロップ剤、液剤、エリキシル剤、エキス剤、チンキ剤、流エキス剤等の経口剤、又は注射剤、点滴剤、クリーム剤、坐剤等の非経口剤のいずれでもよい。 In the present application, those containing glutathione and carnitines in the previous stage as active ingredients are administered. The method of administration is not particularly limited, and parenteral administration such as oral administration, intravenous administration, intraperitoneal administration, or subcutaneous administration can be mentioned. Specifically, oral preparations such as tablets, powders, granules, pills, suspensions, emulsions, soaking agents / decoctions, capsules, syrups, liquids, elixirs, extracts, tinctures, and intravenous extracts. Alternatively, it may be any parenteral preparation such as an injection, a drip, a cream, and a suppository.
本発明の投与量は、前述の機能が発現する量でれば特に限定されない。ヒトに投与する場合の投与量および投与回数は、投与形態、被投与者の年齢、体重等により異なるが、成人一日当り、グルタチオンを通常は５ ０ ｍ ｇ 〜３０ｇ 、好ましくは１００ ｍｇ〜１ ０ｇ、特に好ましくは２００ ｍｇ〜３ｇ、カルニチンは５ｍｇ〜５ｇ 、好ましくは５０ｍｇ〜２ｇ、より好ましくは１００ｍｇ〜１０００ｍｇ、となるように一日一回乃至数回投与する。 The dose of the present invention is not particularly limited as long as it exhibits the above-mentioned functions. The dose and frequency of administration to humans vary depending on the dosage form, age, body weight, etc. of the recipient, but glutathione is usually 50 mg to 30 g, preferably 100 mg to 10 g per day for adults. , Especially preferably 200 mg to 3 g, carnitine 5 mg to 5 g, preferably 50 mg to 2 g, more preferably 100 mg to 1000 mg once or several times a day.
投与間隔は、特に限定されない。継続的に投与することが好ましい。通常は１ 日間〜 １ 年間、好ましくは１ 週間〜３ ヶ月間である。なお、本発明の製剤は、ヒトだけでなく、ヒト以外の動物（ 以下、非ヒト動物と略す）に対しても使用することができる。
The dosing interval is not particularly limited. It is preferable to administer continuously. It is usually 1 day to 1 year, preferably 1 week to 3 months. The preparation of the present invention can be used not only for humans but also for animals other than humans (hereinafter, abbreviated as non-human animals).
以下に実施例により本発明をさらに詳しく説明するが、本発明はこれらの実施例により限定されるものではない。 The present invention will be described in more detail below with reference to Examples, but the present invention is not limited to these Examples.
3T3-L1細胞を3x10^4 cells/ 2 mLになるように6 well plateに播種する。培養2日目、5日目に培地交換を行い、培養7日目に分化誘導培地に交換した。分化誘導培地で培養3日目にインスリン含有培地に変更し、2日毎に培地交換を行いながら12日間培養を続けた。なお、本発明品は分化誘導培地に交換するときから培養終了まで添加した。添加量は、グルタチオンのみ１０００μｇ/ml、カルニチン ２５０、５００μｇ/ml、グルタチオン１０００μｇ/ml及びカルニチン２５０μｇ/ml、グルタチオン１０００μｇ/ml及びカルニチン５００μｇ/mlとした。培養12日目の細胞をオイルレッド染色にて脂肪滴の染色を行い、写真撮影後にイソプロパノールにて色素を抽出し吸光度490nmにて測定を行い、数値化した。結果は、図１に示す。また参考に細胞染色写真を図２に示す。 Seed 3T3-L1 cells on a 6-well plate to 3x10 ^ 4 cells / 2 mL. The medium was exchanged on the 2nd and 5th days of the culture, and the medium was exchanged for a differentiation-inducing medium on the 7th day of the culture. The culture medium was changed to an insulin-containing medium on the 3rd day of culturing with a differentiation-inducing medium, and the culturing was continued for 12 days while exchanging the medium every 2 days. The product of the present invention was added from the time of replacement with the differentiation-inducing medium to the end of culturing. The amount of glutathione added was 1000 μg / ml for glutathione only, 250 μg / ml for carnitine, 1000 μg / ml for glutathione and 250 μg / ml for carnitine, 1000 μg / ml for glutathione, and 500 μg / ml for carnitine. The cells on the 12th day of culture were stained with oil red staining for lipid droplets, and after photography, the dye was extracted with isopropanol and measured at an absorbance of 490 nm to quantify. The results are shown in FIG. A cell-stained photograph is shown in FIG. 2 for reference.
・ 分化誘導培地：
播種培地 100 mL
インスリン（終濃度 10 μｇ/mL） 1 mL
デキサメタゾン（終濃度 2.5 μM） 0.5 mL
イソブチルメチルキサンチン（終濃度 0.5mM） 0.1 mL
・ Differentiation induction medium:
Seed medium 100 mL
Insulin (final concentration 10 μg / mL) 1 mL
Dexamethasone (final concentration 2.5 μM) 0.5 mL
Isobutylmethylxanthine (final concentration 0.5 mM) 0.1 mL
・ インスリン含有培地
播種培地 100 mL
インスリン（終濃度 10 μｇ/mL） 1 mL
・ Insulin-containing medium 100 mL of seeding medium
Insulin (final concentration 10 μg / mL) 1 mL
・ オイルレッド染色（標準プロトコールに従って実施）
準備試薬：
１ Oil Red Oストック溶液：90 mg Oil Red Oを30 mLイソプロパノールに溶かすが、完全には解けない（遮光）
２ 60%イソプロ：イソプロ：蒸留水（DW）=3:2 (90 mL:60 mL)
6 well plate染色：
１ 染色液作成：ストック溶液：DW=3:2 (30mL:20mL)で混合し、0.45 μｍフィルターでろ過し、沈殿除去
２ PBSで洗浄1回後、1mL 4%パラホルムアルデヒドを加えて、1hr 室温静置
３ DWで3回洗浄
４ 染色液2 mL/Well、シェーカーでゆっくり振とうしながら、20 min 室温でインキュベート
５ DWで洗浄、5 min x3回
６ 60%イソプロパノールで洗浄、5 min x3回
７ 画像撮影
８ 100%イソプロを1 mL加えて、5 minインキュベート
９ 200 μL/Well移し、492 nm (490 nm)で測定（Blank=イソプロパノール200 μL）
・ Oil red dyeing (implemented according to standard protocol)
Preparation reagent:
1 Oil Red O stock solution: 90 mg Oil Red O is dissolved in 30 mL isopropanol, but it is not completely dissolved (shading).
2 60% Isopro: Isopro: Distilled water (DW) = 3: 2 (90 mL: 60 mL)
6 well plate staining:
1 Staining solution preparation: Stock solution: Mix with DW = 3: 2 (30 mL: 20 mL), filter with 0.45 μm filter, remove precipitate, wash once with 2 PBS, add 1 mL 4% paraformaldehyde, and room temperature for 1 hr. Stand still 3 Wash 3 times with DW 4 Stain solution 2 mL / Well, incubate at room temperature for 20 min while shaking slowly with shaker 5 Wash with DW, 5 min x 3 times 6 Wash with 60% isopropanol, 5 min x 3 times 7 Imaging 8 Add 1 mL of 100% isopro, incubate for 5 min, transfer 9 200 μL / Well, and measure at 492 nm (490 nm) (Blank = isopropanol 200 μL).
図１の結果より、Ｌ−カルニチン及びグルタチオンを添加した群では、同濃度の単独添加よりも相乗的に脂肪細胞への分化を抑制している。 From the results shown in FIG. 1, the group to which L-carnitine and glutathione were added synergistically suppressed the differentiation into adipocytes as compared with the addition of the same concentration alone.
カルニチン及びグルタチオンの脂肪細胞への分化抑制用組成物となる本発明品は、カルニチンの脂質代謝効果を活性化することが期待されるため、脂質代謝の促進剤、体脂肪蓄積防止剤などとして利用でき、生活習慣病の予防等に適用できる。 The product of the present invention, which is a composition for suppressing the differentiation of carnitine and glutathione into adipocytes, is expected to activate the lipid metabolism effect of carnitine, and is therefore used as a lipid metabolism promoter, a body fat accumulation inhibitor, etc. It can be applied to the prevention of lifestyle diseases.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019082489A JP2020178581A (en) | 2019-04-24 | 2019-04-24 | Fat active metabolism improving composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019082489A JP2020178581A (en) | 2019-04-24 | 2019-04-24 | Fat active metabolism improving composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2020178581A true JP2020178581A (en) | 2020-11-05 |
Family
ID=73022628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082489A Pending JP2020178581A (en) | 2019-04-24 | 2019-04-24 | Fat active metabolism improving composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2020178581A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11130944B2 (en) | 2013-01-16 | 2021-09-28 | Genomatica, Inc. | Acyl-ACP reductase with improved properties |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002542191A (en) * | 1999-04-16 | 2002-12-10 | シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ | Carnitine and glutathione-containing compositions useful for increasing glutathione absorption and enhancing its effect |
| JP2007519678A (en) * | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | Nutritional composition for improving skin condition and preventing skin diseases |
| JP2008143811A (en) * | 2006-12-07 | 2008-06-26 | Nisshin Pharma Inc | Lipid metabolism promoting composition |
-
2019
- 2019-04-24 JP JP2019082489A patent/JP2020178581A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002542191A (en) * | 1999-04-16 | 2002-12-10 | シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ | Carnitine and glutathione-containing compositions useful for increasing glutathione absorption and enhancing its effect |
| JP2007519678A (en) * | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | Nutritional composition for improving skin condition and preventing skin diseases |
| JP2008143811A (en) * | 2006-12-07 | 2008-06-26 | Nisshin Pharma Inc | Lipid metabolism promoting composition |
Non-Patent Citations (1)
| Title |
|---|
| 世界のウェブアーカイブ｜株式会社カプセル・マーケッツのウェブサイトに掲載された栄養機能食品「アディポ, JPN6023005488, ISSN: 0004992049 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11130944B2 (en) | 2013-01-16 | 2021-09-28 | Genomatica, Inc. | Acyl-ACP reductase with improved properties |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100415224C (en) | Compositions comprising fatty acids and amino acids | |
| Li et al. | Role of carnitine in non-alcoholic fatty liver disease and other related diseases: an update | |
| WO2007049818A1 (en) | Anti-fatty liver, anti-obesity or hypolipidemic composition | |
| JP5085541B2 (en) | Fatigue reducing agent | |
| US20080038321A1 (en) | Prophylactic/therapeutic compositions for liver diseases | |
| US6608109B2 (en) | Composition comprising L-arginine as a muscle growth stimulant and use thereof | |
| JP6440843B2 (en) | Use of a composition comprising a ferrous amino acid chelate for the manufacture of a medicament for the regulation of fat metabolism | |
| WO2004019928A1 (en) | Therapeutic agent for hepatic disease | |
| EP3064209B1 (en) | Composition comprising ginsenoside f2 for preventing or treating insulin resistance | |
| SG184771A1 (en) | Compositions incorporating sesamin-class compounds and vitamin b1 class compounds | |
| JPWO2003006037A1 (en) | Therapeutic agent | |
| JP2020178581A (en) | Fat active metabolism improving composition | |
| JP3908513B2 (en) | Liver function improving agent | |
| US6887499B2 (en) | Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease | |
| EP2773363A1 (en) | Nutritional supplement for weight management | |
| Davidova et al. | Pharmacological activity of amino acids and prospects for the creation of drugs based on them | |
| EP4331583A1 (en) | Blood carnitine-increasing agent | |
| JP2007230987A (en) | Anti-obestic agent | |
| JPWO2007077995A1 (en) | Muscle bulking agent | |
| US6465021B2 (en) | Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease | |
| KR101613252B1 (en) | Compositions for Preventing or Treating Obesity and Fatty Liver Containing Ariginase Inhibitors | |
| ES2284546T3 (en) | FOOD COMPOSITIONS AND METHODS OF PREPARATION OF THE SAME. | |
| JP2016074617A (en) | Fat accumulation inhibitor | |
| Bisht et al. | Amino acid: Essential builiding blocks for Human body | |
| JPS6210018A (en) | Composition for suppressing obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220318 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230414 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231030 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240118 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240321 |